Nuvectis Pharma reported total assets of $22.38M and total liabilities of $13.29M for the quarter ended Jun 2026, down 17.1% year over year. This balance sheet covers 21 quarters of results from Jun 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||
| Current Assets | |||||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 5.74M | 16.70M | 13.60M | 23.64M | 19.99M | 15.50M | 24.60M | 22.10M | 19.13M | 19.50M | 18.12M | 17.20M | 18.53M | 29.90M | 26.80M | 35.44M | 31.63M | 25.13M | 22.20M | ||
| Prepaid Assets | 0.09M | 0.93M | 0.67M | 1.23M | 0.41M | 0.74M | 0.34M | 0.20M | 0.06M | 0.25M | 0.18M | 0.14M | 0.07M | 0.28M | 0.21M | 0.14M | 0.07M | 0.27M | 0.22M | ||
| Current Assets | 5.83M | 17.62M | 14.24M | 24.87M | 20.41M | 16.21M | 24.94M | 22.26M | 19.18M | 19.71M | 18.30M | 17.31M | 18.61M | 30.15M | 27.01M | 35.59M | 31.71M | 25.40M | 22.38M | ||
| Non-Current Assets | |||||||||||||||||||||
| Non-Current Assets | 0.82M | ||||||||||||||||||||
| Assets | 6.66M | 17.62M | 14.24M | 24.87M | 20.41M | 16.21M | 24.94M | 22.26M | 19.18M | 19.71M | 18.30M | 17.31M | 18.61M | 30.15M | 27.01M | 35.59M | 31.71M | 25.40M | 22.38M | ||
| Liabilities | |||||||||||||||||||||
| Current Liabilities | |||||||||||||||||||||
| Accounts Payables | 1.06M | 1.35M | 1.43M | 2.25M | 2.91M | 2.10M | 1.80M | 3.49M | 2.77M | 1.76M | 1.85M | 2.26M | 2.50M | 2.99M | 4.98M | 6.44M | 6.27M | 4.70M | 5.18M | ||
| Payables | 1.06M | 1.35M | 1.43M | 2.25M | 2.91M | 2.10M | 1.80M | 3.49M | 2.77M | 1.76M | 1.85M | 2.26M | 2.50M | 2.99M | 4.98M | 6.44M | 6.27M | 4.70M | 5.18M | ||
| Accumulated Expenses | 0.40M | 0.70M | 0.79M | 0.86M | 2.38M | 1.68M | 1.84M | 1.93M | 3.80M | 3.45M | 3.61M | 3.77M | 5.56M | 5.04M | 5.08M | 5.00M | 6.91M | 6.45M | 6.63M | ||
| Total Current Liabilities | 2.42M | 3.06M | 2.74M | 4.49M | 6.19M | 3.93M | 4.61M | 5.58M | 6.98M | 5.69M | 5.77M | 6.32M | 8.89M | 9.19M | 10.13M | 11.58M | 13.30M | 11.18M | 13.29M | ||
| Non-Current Liabilities | |||||||||||||||||||||
| Non-Current Deffered Revenue | 0.82M | ||||||||||||||||||||
| Preferred Stock Liabilities | 15.25M | 15.25M | |||||||||||||||||||
| Total Non-Current Liabilities | 6.19M | 6.98M | 8.89M | 13.30M | |||||||||||||||||
| Total Liabilities | 8.93M | 2.42M | 3.06M | 2.74M | 4.49M | 6.19M | 3.93M | 4.61M | 5.58M | 6.98M | 5.69M | 5.77M | 6.32M | 8.89M | 9.19M | 10.13M | 11.58M | 13.30M | 11.18M | 13.29M | |
| Shareholder's Equity | |||||||||||||||||||||
| Common Equity | -8.93M | -11.01M | 14.56M | 11.50M | 20.37M | 14.22M | 12.27M | 20.33M | 16.69M | 12.20M | 14.02M | 12.53M | 10.99M | 9.71M | 20.95M | 16.87M | 24.01M | 18.41M | 14.22M | 9.08M | |
| Liabilities and Shareholders Equity | 6.66M | 17.62M | 14.24M | 24.87M | 20.41M | 16.21M | 24.94M | 22.26M | 19.18M | 19.71M | 18.30M | 17.31M | 18.61M | 30.15M | 27.01M | 35.59M | 31.71M | 25.40M | 22.38M | ||
| Retained Earnings | -12.90M | 30.40M | 30.91M | 45.66M | 46.20M | 48.31M | 62.07M | 64.31M | 66.45M | 72.44M | 75.37M | 77.99M | 82.96M | 99.53M | 101.78M | 116.38M | 118.10M | 119.96M | 121.84M | ||
| Treasury Shares | 5.01M | 5.01M |